Singapore, Sept. 11 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherap... Read More
Singapore, Sept. 11 -- The Health Sciences Authority received information related to the study titled 'A single-ascending and multiple-ascending dose study to evaluate the safety, tolerability, pharma... Read More
Singapore, Sept. 11 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pemb... Read More
Singapore, Sept. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and E... Read More
Singapore, Sept. 11 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of P... Read More
Singapore, Sept. 11 -- The Health Sciences Authority received information related to the study titled 'An Open-Label, Rollover Study for Participants with Thyroid Eye Disease Previously Enrolled in Am... Read More
Singapore, Sept. 11 -- The Health Sciences Authority received information related to the study titled 'An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Struc... Read More
Singapore, Sept. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Randomized, Crossover Study to Investigate the Relative Bioavailability of... Read More
Singapore, Sept. 11 -- The Health Sciences Authority received information related to the study titled 'Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent ... Read More
Singapore, Sept. 11 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-based Combina... Read More